Remission of type 2 diabetes depends on prompt comprehensive lifestyle changes upon diagnosis: How can this "Road to Damascus" experience be supported?
- PMID: 35430168
- DOI: 10.1016/j.joim.2022.04.001
Remission of type 2 diabetes depends on prompt comprehensive lifestyle changes upon diagnosis: How can this "Road to Damascus" experience be supported?
Abstract
Theoretically, a new diagnosis of type 2 diabetes mellitus (T2DM) requires a dramatic change in an individual's way of life. Weight loss and physical activity can lead to remission of diabetes, which has been associated with a lower risk of developing complications. Today, the importance of a healthy lifestyle is further highlighted by data showing that obesity and diabetes increase the risk of severe complications from coronavirus disease 2019. However, remission rarely occurs in reality, probably due to the inability of people with T2DM to adhere to the intensive lifestyle interventions that are necessary. The complexity of contributing factors may explain why making these changes is so challenging and underscore the fact that there is no magical solution for T2DM. Instead, hard work from both patients and health care providers is needed for the conversion to be achieved. This article calls for more research on the underlying reasons why adhering to a healthy way of life is so difficult for people with diabetes and obesity. Clearly defining these barriers would facilitate the planning of effective policies to promote the adoption of appropriate lifestyle changes early in the course of the disease.
Keywords: Diet; Exercise; Lifestyle change; Remission; Type 2 diabetes.
Copyright © 2022 Shanghai Changhai Hospital. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest TK has received honoraria as a speaker from AstraZeneca, Boehringer Ingelheim, Pharmaserve Lilly and Novo Nordisk and has participated in sponsored studies by Eli-Lilly. KK has received honoraria for lectures/advisory boards and research support from AstraZeneca, Boehringer Ingelheim, Pharmaserve Lilly, Sanofi-Aventis, ELPEN, MSD, and Novo Nordisk. NP has been an advisory board member of AstraZeneca, Boehringer Ingelheim, MSD, Novo Nordisk, Pfizer, Takeda and TrigoCare International; has participated in sponsored studies by Astra-Zeneca, Eli-Lilly, GSK, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for AstraZeneca, Boehringer Ingelheim, Eli-Lilly, Elpen, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis and Vianex; and attended conferences sponsored by TrigoCare International, Eli-Lilly, Galenica, Novo Nordisk, Pfizer and Sanofi-Aventis.
Similar articles
-
Diabetes Intervention Accentuating Diet and Enhancing Metabolism (DIADEM-I): a randomised controlled trial to examine the impact of an intensive lifestyle intervention consisting of a low-energy diet and physical activity on body weight and metabolism in early type 2 diabetes mellitus: study protocol for a randomized controlled trial.Trials. 2018 May 21;19(1):284. doi: 10.1186/s13063-018-2660-1. Trials. 2018. PMID: 29784059 Free PMC article.
-
A lifestyle program of exercise and weight loss is effective in preventing and treating type 2 diabetes mellitus: Why are programs not more available?Prev Med. 2015 Nov;80:50-2. doi: 10.1016/j.ypmed.2015.03.014. Epub 2015 Mar 24. Prev Med. 2015. PMID: 25818810 Free PMC article.
-
Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial.JAMA Surg. 2015 Oct;150(10):931-40. doi: 10.1001/jamasurg.2015.1534. JAMA Surg. 2015. PMID: 26132586 Free PMC article. Clinical Trial.
-
Lifestyle modifications and surgical options in the treatment of patients with obesity and type 2 diabetes mellitus.Postgrad Med. 2012 Jul;124(4):168-80. doi: 10.3810/pgm.2012.07.2578. Postgrad Med. 2012. PMID: 22913905 Review.
-
Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity.Diabetes Care. 2001 Jan;24(1):117-23. doi: 10.2337/diacare.24.1.117. Diabetes Care. 2001. PMID: 11194216 Review.
Cited by
-
The associations between social support, self-regulatory fatigue, and health-promoting behaviors among people with type 2 diabetes mellitus: a cross-sectional survey.Front Public Health. 2023 Dec 14;11:1281065. doi: 10.3389/fpubh.2023.1281065. eCollection 2023. Front Public Health. 2023. PMID: 38155890 Free PMC article.
-
A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity.J Obes. 2024 May 10;2024:8056440. doi: 10.1155/2024/8056440. eCollection 2024. J Obes. 2024. PMID: 38765635 Free PMC article. Review.
-
The use of metformin for type 2 diabetes prevention: Observational multicenter study from Saudi Arabia.Front Public Health. 2022 Sep 8;10:989072. doi: 10.3389/fpubh.2022.989072. eCollection 2022. Front Public Health. 2022. PMID: 36159298 Free PMC article.
-
Drawing lines in the sand: The growing threat of obesity in type 1 diabetes.World J Diabetes. 2024 May 15;15(5):823-827. doi: 10.4239/wjd.v15.i5.823. World J Diabetes. 2024. PMID: 38766422 Free PMC article.
-
Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?Drugs. 2023 Apr;83(6):469-477. doi: 10.1007/s40265-023-01852-1. Epub 2023 Mar 21. Drugs. 2023. PMID: 36941489
MeSH terms
LinkOut - more resources
Full Text Sources
Medical